Study guide

8.3 Medical Oncology & Oncological Emergencies

MRCPI in General Medicine Part I Written

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Structure, Strategy & Foundation

1.1 MRCPI Part I Format, Scoring & Standard-Setting 1.2 RCPI BST Curriculum & Single-Best-Answer Exam Strategy

2 Chapter 2: Cardiology & Vascular Medicine

2.1 Acute Coronary Syndromes & Stable Angina 2.2 Tachyarrhythmias, Bradyarrhythmias & Channelopathies 2.3 Heart Failure & Valvular Heart Disease 2.4 Hypertension, Vascular & Pericardial Diseases

3 Chapter 3: Respiratory Medicine

3.1 Asthma, COPD & Airway Diseases 3.2 Pneumonia, Tuberculosis & Respiratory Infections 3.3 Interstitial Lung Disease & Pleural Disorders 3.4 Pulmonary Embolism, Pulmonary Hypertension & Sleep Apnoea

4 Chapter 4: Gastroenterology & Hepatology

4.1 Upper & Lower GI Disorders & Inflammatory Bowel Disease 4.2 Acute & Chronic Liver Disease 4.3 Pancreatitis, Biliary Tract & GI Bleeding 4.4 Malabsorption, GI Motility & Clinical Nutrition

5 Chapter 5: Nephrology & Acid-Base Disorders

5.1 Acute Kidney Injury & Glomerular Diseases 5.2 Chronic Kidney Disease & Renal Replacement Therapy 5.3 Electrolyte Imbalances & Acid-Base Disorders

6 Chapter 6: Endocrinology & Diabetes

6.1 Diabetes Mellitus & Metabolic Complications 6.2 Thyroid & Calcium Disorders 6.3 Adrenal, Pituitary & Endocrine Syndromes

7 Chapter 7: Rheumatology & Clinical Immunology

7.1 Inflammatory Arthritides 7.2 Systemic Autoimmune & Vasculitic Diseases 7.3 Metabolic Bone Disease & Clinical Immunology

8 Chapter 8: Haematology & Medical Oncology

8.1 Anaemias, Haemostasis & Thrombosis 8.2 Leukaemias, Lymphomas & Plasma Cell Disorders 8.3 Medical Oncology & Oncological Emergencies

9 Chapter 9: Neurology & Dermatology

9.1 Stroke & Cerebrovascular Diseases 9.2 Epilepsy, Headache & Movement Disorders 9.3 Neuromuscular & Peripheral Nerve Disorders 9.4 Cutaneous Manifestations of Systemic Disease

10 Chapter 10: Acute Medicine, Critical Care & Geriatrics

10.1 Acute Poisoning & Toxidromes 10.2 Sepsis, Shock & Resuscitation 10.3 Geriatric Syndromes, Frailty & Comprehensive Care

11 Chapter 11: Clinical Pharmacology & Therapeutics

11.1 Pharmacokinetics & Pharmacodynamics 11.2 High-Risk Drug Classes & Prescribing Safety 11.3 Adverse Drug Reactions & Drug Safety

12 Chapter 12: Basic Sciences, Biostatistics & Clinical Ethics

12.1 Applied Cardiovascular & Respiratory Physiology 12.2 Clinical Biochemistry, Molecular Genetics & Microbiology 12.3 Biostatistics, Evidence-Based Medicine & Ethics

8.3 Medical Oncology & Oncological Emergencies

Key Takeaways Explain This Topic AI

Neutropenic sepsis is defined as absolute neutrophil count (ANC) <0.5 x 10^9/L (or <1.0 x 10^9/L with predicted drop to <0.5) with temperature >38.0°C or signs of sepsis; empiric broad-spectrum IV antibiotics (e.g. piperacillin-tazobactam) MUST be administered within 1 hour.

Tumor Lysis Syndrome (TLS) is characterized by hyperuricemia (>476 µmol/L), hyperkalemia (>6.0 mmol/L), hyperphosphatemia (>1.45 mmol/L), and hypocalcemia (<1.75 mmol/L); rasburicase (recombinant urate oxidase) is first-line treatment for high-risk patients.

Metastatic Spinal Cord Compression (MSCC) requires immediate intravenous dexamethasone (16 mg daily) and urgent whole-spine MRI within 24 hours followed by neurosurgical decompression or emergency radiotherapy.

Hypercalcaemia of Malignancy (serum calcium >3.0 mmol/L adjusted) is treated initially with aggressive IV 0.9% sodium chloride rehydration (3–4 L/24 hours) followed by IV bisphosphonates (zoledronic acid 4 mg over 15 mins or pamidronate 60–90 mg).

Superior Vena Cava Obstruction (SVCO) presenting with facial oedema, venous distension, and stridor requires oxygen, high-dose dexamethasone, and urgent endovascular stenting or emergency radiotherapy.

Last updated: October 2026

  • 8.3 Medical Oncology & Oncological Emergencies
  • Acute Oncological Emergencies: Resuscitation & Risk Stratification

Oncological emergencies represent life-threatening complications resulting directly from systemic malignancy or cytotoxic cancer therapy. Rapid identification and immediate protocol-driven interventions are crucial to prevent irreversible organ damage or mortality.

1. Neutropenic Sepsis

Neutropenic sepsis is a medical emergency occurring in cancer patients receiving myelosuppressive chemotherapy.

Diagnostic Definition & Clinical Criteria

Neutropenia: Absolute Neutrophil Count (ANC) <0.5 x 10^9/L , or expected to fall below 0.5 x 10^9/L within 48 hours.

Fever / Sepsis: Single oral temperature >38.3°C , or persistent temperature >38.0°C for over 1 hour, or any clinical signs/symptoms of systemic sepsis (hypotension, tachycardia, altered mental state) regardless of temperature.

Management & Risk Stratification Protocol

Empiric intravenous antibiotic therapy MUST be initiated within 1 hour of arrival ("door-to-needle time"), prior to receiving blood culture results or imaging.

  • Clinical Parameter Low-Risk Neutropenic Sepsis High-Risk Neutropenic Sepsis
  • MASCC Risk Index Score ≥21 points <21 points

Clinical Presentation Outpatient, hemodynamically stable, no organ dysfunction Inpatient, septic shock, pneumonia, severe mucositis, renal failure

Expected Duration of Neutropenia Short (<7 days) Prolonged (≥7 days)

Empiric Antibiotics Oral fluoroquinolone (Ciprofloxacin) + Co-amoxiclav (outpatient) IV Piperacillin-tazobactam (4.5 g 6-hourly) OR Meropenem (1 g 8-hourly)

Addition of Vancomycin / Teicoplanin Not routinely indicated Indicated for catheter infection, severe mucositis, MRSA colonisation, shock

MRCPI Exam Pearl: Do not delay antibiotic administration to obtain central line cultures or imaging. If a patient is penicillin-allergic (severe anaphylaxis), administer IV Meropenem or Ciprofloxacin plus Vancomycin.

2. Tumor Lysis Syndrome (TLS)

Tumor Lysis Syndrome occurs due to rapid, massive destruction of malignant cells (commonly in high-grade haematological malignancies like Burkitt lymphoma, ALL, or bulky AML) releasing intracellular contents into the systemic circulation.

Cairo-Bishop Diagnostic Criteria for TLS

Laboratory TLS requires ≥2 of the following biochemical abnormalities within 3 days before or 7 days after initiation of chemotherapy:

  • Biochemical Parameter Laboratory Threshold Percentage Change Clinical Manifestations
  • Hyperuricemia >476 µmol/L (>8.0 mg/dL) 25% increase from baseline Urate nephropathy, acute kidney injury
  • Hyperkalemia >6.0 mmol/L (>6.0 mEq/L) 25% increase from baseline Cardiac dysrhythmias, sudden cardiac death

Hyperphosphatemia >1.45 mmol/L (>4.5 mg/dL) 25% increase from baseline Calcium-phosphate crystallization, renal failure

Hypocalcemia <1.75 mmol/L (<7.0 mg/dL) 25% decrease from baseline Tetany, seizures, QT prolongation, carpopedal spasm

Clinical TLS is defined as Laboratory TLS PLUS at least one clinical complication: acute kidney injury (creatinine ≥1.5x upper limit of normal), cardiac arrhythmia, or seizures.

TLS Prophylaxis & Treatment Strategy

Vigorous Hydration: Intravenous 0.9% sodium chloride at 3 L/m²/24 hours to maintain high urine output (>100 mL/m²/hour).

Hypouricemic Agents:

Allopurinol (300 mg daily): Xanthine oxidase inhibitor. Prevents new uric acid formation. Indicated for low/intermediate risk TLS.

Rasburicase (0.2 mg/kg IV): Recombinant urate oxidase enzyme. Converts existing insoluble uric acid into soluble allantoin for excretion. Indicated for high-risk TLS or established hyperuricemia. (Contraindicated in G6PD deficiency due to risk of severe haemolysis and methemoglobinemia).

3. Metastatic Spinal Cord Compression (MSCC)

MSCC occurs when metastatic tumor tissue compresses the spinal cord or cauda equina, most frequently originating from prostate, breast, or lung carcinoma.

Clinical Presentation & Diagnostic Emergency

Symptoms: Progressive axial back pain (worse lying flat, nocturnal, coughing), bilateral lower limb weakness, sensory level deficit, and sphincter dysfunction (urinary retention/overflow, faecal incontinence).

Gold-Standard Investigation: Urgent Whole-Spine MRI performed within 24 hours of clinical presentation (or <12 hours if rapid neurological deterioration).

Emergency Management Algorithm

High-Dose Corticosteroids: Immediately administer IV Dexamethasone 16 mg (as 16 mg single dose or 8 mg BD) with oral proton pump inhibitor cover to reduce vasogenic cord oedema.

Patient Positioning: Strict flat bed rest with log-rolling until spinal stability is formally assessed.

Definitive Treatment:

Neurosurgical Decompression & Stabilization: Preferred for patients with spinal instability, single-level compression, unknown primary tumor, or previous radiotherapy to the site.

Radiotherapy: Preferred for radio-sensitive tumors (lymphoma, myeloma, small cell lung cancer) or non-surgical candidates.

  • 4. Hypercalcaemia of Malignancy & SVCO
  • Hypercalcaemia of Malignancy

Driven by parathyroid hormone-related peptide (PTHrP) secretion (squamous cell carcinomas) or osteolytic bone metastases (breast cancer, multiple myeloma).

Clinical Features: "Stones, bones, abdominal groans, and psychic moans" (polyuria, polydipsia, confusion, constipation, shortening of QT interval).

Emergency Management:

Volume Expansion: IV 0.9% Sodium Chloride 3 to 4 Litres in 24 hours to restore GFR and promote calciuresis.

Bisphosphonates: IV Zoledronic Acid 4 mg over 15 minutes (or IV Pamidronate 60–90 mg over 2–4 hours) administered after adequate rehydration. Onset of action is 24–48 hours; peak effect at 4–7 days.

Denosumab: Monoclonal RANKL inhibitor (120 mg subcutaneous) for refractory hypercalcaemia or severe renal impairment.

Superior Vena Cava Obstruction (SVCO)

Obstruction of blood flow through the SVC caused by mediastinal mass (non-small cell lung cancer 50%, small cell lung cancer 25%, lymphoma 15%).

Clinical Presentation: Facial and neck swelling, dyspnoea, cough, distended neck/chest wall veins, and Pemberton's sign. Stridor indicates critical upper airway compromise.

Emergency Management: Elevate head of bed, high-dose IV dexamethasone (16 mg daily), oxygen therapy, and urgent percutaneous endovascular stenting (provides rapid relief within 24–48 hours) or emergency radiotherapy/chemotherapy depending on histology.